dual anti-CD19/anti-CD22 CAR T-cell therapy (Seattle Children's Hospital)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug Namedual anti-CD19/anti-CD22 CAR T-cell therapy (Seattle Children's Hospital)
Drug Alias Namedual anti-CD19/anti-CD22 CAR T-cell therapy (Seattle Children's Hospital/CureWorks)SCRI-CAR19X22v1
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCD22 modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesCureWorksSeattle Children'S Hospital
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A